A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Arm Study to Investigate the Efficacy and Safety of Inhaled Laninamivir Octanoate TwinCaps Dry Powder Inhaler in Adults With Symptomatic Influenza A or B Infection

Trial Profile

A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Arm Study to Investigate the Efficacy and Safety of Inhaled Laninamivir Octanoate TwinCaps Dry Powder Inhaler in Adults With Symptomatic Influenza A or B Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Laninamivir (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Therapeutic Use
  • Acronyms IGLOO
  • Sponsors Biota Pharmaceuticals
  • Most Recent Events

    • 03 Aug 2017 This trial has been discontinued in Belgium.
    • 09 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Aug 2014 Status changed from recruiting to active, no longer recruiting, according to a Biota Pharmaceuticals media release, which reported 639 patients were enrolled between June 2013 and April 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top